申请人:Dainippon Sumitomo Pharma Co., Ltd.
公开号:EP1736467A1
公开(公告)日:2006-12-27
A compound of the formula (1):
wherein
m, n and p is independently an integer of 0 to 4 with the proviso that 3 ≦ m + n ≦ 8; X is the formula: NR4, etc.; R1, R3 and R4 are a substituted or unsubstituted aryl group, etc.; R2 is a hydrogen atom, etc.; a, b, c, d, e and f are a hydrogen atom or a substituted or unsubstituted alkyl group, etc.; Y is the formula: -SO2-, etc.; and Z is an oxygen atom, etc.;
or a prodrug thereof or a pharmaceutically acceptable salt of the same has an activity of potentiating an expression of a low density lipoprotein receptor and thus is useful as an agent for treating hyperlipidemia or arteriosclerosis.
式 (1) 的化合物:
其中
m、n 和 p 独立地为 0 至 4 的整数,但 3 ≦ m + n ≦ 8;X 为式中的NR4等;R1、R3和R4是取代或未取代的芳基等;R2是氢原子等;a、b、c、d、e和f是氢原子或取代或未取代的烷基等;Y是式:-SO2-等:-SO2-等;Z是氧原子等;
或其原药或其药学上可接受的盐具有增强低密度脂蛋白受体表达的活性,因此可用作治疗高脂血症或动脉硬化的药物。